Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Table 6 Univariate and multivariable analysis of PFS and OS in all patients (N = 186)

Risk Factor	Univariate analysis						Multivariable analysis^a
	PFS	OS	PFS	OS
	HR	95 % CI	P	HR	95 % CI	P	HR	95 % CI	P	HR	95 % CI	P
Prior capecitabine vs. no prior capecitabine	1.50	1.12-2.02	0.0072	1.33	0.97-1.83	0.0790	1.22	0.89-1.67	0.2140	0.73	0.48-1.10	0.1351
Hormone receptor positive vs. hormone receptor negative	0.78	0.57-1.06	0.1064	0.80	0.57-1.11	0.1741
Best systemic response SD, PD vs. CR, PR	2.54	1.85-3.48	<0.0001	1.88	1.33-2.64	0.0003	2.60	1.87-3.63	<0.0001	1.31	0.86-1.99	0.2064
Median prior trastuzumab duration, wks ≥24.1 vs. <24.1	0.68	0.50-0.91	0.0108	0.57	0.41-0.78	0.0006	0.66	0.48-0.89	0.0074	0.68	0.48-0.96	0.0271
Age ≥50 vs. <50	0.89	0.66-1.20	0.4418	0.84	0.61-1.15	0.2726
No. of metastasis ≥3 vs. <3	1.16	0.86-1.16	0.3427	1.64	1.18-2.28	0.0034				1.78	1.23-2.58	0.0023
No. of prior chemotherapy regimens >3 vs. ≤3	1.17	0.86-1.58	0.3214	1.58	1.14-2.19	0.0067				1.64	1.08-2.47	0.0194
Pattern of metastasis Visceral only vs. other	1.58	1.17-2.15	0.0031	0.98	0.70-1.36	0.8928	1.61	1.18-2.21	0.0031
Median TTP, wks ≥20.0 vs. <20.0				0.36	0.26-0.50	<0.0001				0.37	0.25-0.56	<0.0001
Brain metastasis vs. no brain metastasis	0.98	0.71-1.35	0.8979	1.23	0.88-1.74	0.2310

^a Risk factors were determined using univariate Cox’s proportional hazards regression (α <0.10).
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTP, time to disease progression.
HR, hazard ratio; CI, confidence interval.

ISSN: 1471-2407